KIWOOM SECURITIES
VC Fund
Yeoksamdong, South Korea
KIWOOM SECURITIES is a VC fund in Yeoksamdong focused on Pharmaceutical and Software. Security Company in Korea
- Total investments:
- 37
- Last investment:
- Lead investor:
- 11%
Last updated:
For AI agents: llms.txt
Industries KIWOOM SECURITIES invests in
Stages KIWOOM SECURITIES invests in
Countries KIWOOM SECURITIES invests in
Round sizes
Round size
- Series A
- $3M–$21M
- Series B
- $4.2M–$25M
- Venture - Series Unknown
- $3.5M–$46M
Investment Focus
Industry
- Pharmaceutical 7 (19%)
- Software 6 (16%)
- Health Care 5 (14%)
- Manufacturing 4 (11%)
- Information Technology 4 (11%)
Stage
- Series B 11 (30%)
- Venture - Series Unknown 9 (24%)
- Series A 6 (16%)
- Seed 2 (5%)
- Series C 2 (5%)
Country
- South Korea 31 (84%)
- Indonesia 1 (3%)
- United States 1 (3%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Namyangju Maseok IDC
|
Namyangju Maseok IDC is a Special Purpose Company established to develop and operate a massive commercial Artificial Intelligence (AI) data center. | $20.5M / Seed / Jul 24, 2026 | |
| Park Systems Corp. is a manufacturer of atomic force microscopy (AFM) systems, with a complete range of products for researchers and engineers in the chemistry, materials, physics, life sciences, semiconductor and data storage industries. | $65.2M / Post-IPO Debt / Jun 08, 2026 | ||
| BNB Korea is a cosmetics OEM company famous for its horse oil cream. BNB Korea is engaged in manufacturing skincare, makeup, masks, hair, fragrance and industrial cosmetic products, enabling clients to take care of their skin. | $18.1M / Venture - Series Unknown / May 13, 2026 | ||
| 3billion was founded with the goal of ending the diagnostic odyssey of rare disease patients through comprehensive genetic testing. It has reduced the amount of time and cost that was previously required for genome interpretation by using bioinformatics and machine learning technology, making genome-scale rare disease genetic testing affordable forpatients in need.The company was established in 2016 and is headquartered in Seoul, South Korea. | $11.8M / Post-IPO Equity / Apr 23, 2026 | ||
| Ticaros is a biotech company that develops immune anti-cancer drugs. | $14M / Series D / Mar 03, 2026 | ||
| ATsens is suggesting comprehensive way to care the health of human being. Heart of the body is the Heart | $9.3M / Venture - Series Unknown / Feb 26, 2026 | ||
| Meissa is a drone-based construction tech startup that provides real-time 3D mapping and modeling. The company digitalizes sites with spatial data, such as design level comparison, and overlays floor plans collected by drone, as well as does three-dimensional modeling of projects, enabling companies to complete construction smartly. | $6.8M / Venture - Series Unknown / Dec 23, 2025 | ||
| Lutem Bio is an online medicine firm that is intended for general health. The company provides medicine for memory, cognition, immunity, gut, joints, and bones, among others, enabling customers to get medicines recommended by a doctor. | $3M / Series A / Oct 17, 2025 | ||
| PEOPLE AND TECHNOLOGY provides DX-based AI solutions on INDOOR GEOLOCATION AND SMART SENSING through its INDOORPLUS+ IoT, Location Based System (LBS) and Real Time Location System (RTLS) platform in the fields of healthcare, manufacturing, defense, smart cities, and the public sector.More than 100 corporate customers in various business sectorssuch as healthcare, banking, manufacturing, retail, energy and public services have already chosen PEOPLE AND TECHNOLOGY to deploy industry grade solutions for employee safety, asset tracking & monitoring, security & access control, flow management and process efficiency. They have gained improvements in productivity and process efficiency while reducing their corporate risks and optimizing their procurement. Since its foundation in 2013, PEOPLE AND TECHNOLOGY has become a leading provider in South Korea and is expanding overseas. | $5.1M / Series C / May 21, 2025 | ||
| TESSA is an alternative investment platform for the purchase, sale, and trade of fractionalized ownership interests in investment-grade blue-chip artwork (such as Warhol, Picasso, Kusama, Basquiat, etc.) with the accessibility and liquidity of public markets. The platform enables white-listed “micro-collectors” to co-own fractional ownershipinterests in curated blue-chip artwork represented in digital form on a public blockchain. TESSA manages all maintenance and administrative services relating to the artwork which is publicly promoted and displayed to enhance its value and broaden its exposure to the art-viewing public.The platform provides transparent and safe management of ownership certificates, transaction history, and transfer status through a blockchain network and secure third-party service providers. | $6.4M / Series A / Apr 18, 2024 | ||
| See all 37 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does KIWOOM SECURITIES invest in?
KIWOOM SECURITIES invests primarily in Pharmaceutical, Software and Health Care startups, most often at Series B and Venture - Series Unknown stage. Most of the 37 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is KIWOOM SECURITIES's check size?
KIWOOM SECURITIES typically joins rounds of $3M–$21M at Series A, $4.2M–$25M at Series B and $3.5M–$46M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds KIWOOM SECURITIES participates in.
When did KIWOOM SECURITIES last invest?
The most recent investment recorded for KIWOOM SECURITIES closed in Jul 2026. Shizune tracks 37 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
